MORGAN ENNIS: Open Payments
NPI 1932843158 · MACON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$474 in 25 payments from 14 companies in 2025. Trend: 2023 $298 · 2024 $601 · 2025 $474
Food & beverage: $474
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $93 |
| Noven Therapeutics, LLC | 4 | $65 |
| ABBVIE INC. | 2 | $53 |
| Lilly USA, LLC | 3 | $48 |
| GlaxoSmithKline, LLC. | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Seqirus USA Inc | 1 | $24 |
| Medtronic, Inc. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: Ozempic, Xelstrym, MOUNJARO, TRELEGY ELLIPTA, LINZESS, GEMTESA, Fluad, UBRELVY.
Industry payments across GA — which companies pay providers there.
